甲磺酸阿帕替尼二线治疗晚期非小细胞肺癌的临床疗效

Clinical efficacy of apatinib mesylate as second-line treatment in advanced non-small cell lung cancer

目的探讨甲磺酸阿帕替尼二线治疗晚期非小细胞肺癌的临床疗效。方法 120例一线化疗后进展的晚期非小细胞肺癌患者作为研究对象,依据随机法分为对照组与观察组,各60例。对照组进行GP方案化疗治疗,观察组进行阿帕替尼二线治疗。对比两组患者的治疗效果及不良反应发生情况。结果两组均无完全缓解(CR)患者,观察组患者的疾病控制率(DCR)为68.3%,高于对照组的43.3%,差异具有统计学意义(P<0.05)。观察组患者的骨髓抑制发生率为40.0%、恶心呕吐发生率为13.3%,均低于对照组的78.3%、75.0%,差异均具有统计学意义(P<0.05);两组患者的黏膜炎、血压升高、蛋白尿、手足麻木发生率对比,差异均无统计学意义(P>0.05)。结论甲磺酸阿帕替尼二线治疗晚期非小细胞肺癌具有明显疗效,不良反应可控,可作为二线治疗非小细胞肺癌的靶向药物。

Objective To discuss the clinical efficacy of apatinib mesylate as second-line treatment in advanced non-small cell lung cancer.Methods A total of 120 cases of advanced non-small cell lung cancer patients progressed after first-line chemotherapy as research subjects were randomly divided into control group and observation group,with 60 cases in each group.The control group received GP chemotherapy and the observation group received apatinib as second-line treatment.The therapeutic effect and occurrence of adverse reactions were compared between the two groups.Results There was no complete remission(CR)cases in the two groups.The disease control rate(DCR)of the observation group was 68.3%,which was higher than 43.3%of the control group,and the difference was statistically significant(P<0.05).The incidence of myelosuppression and nausea and vomiting of the observation group were 40.0%and 13.3%,which were lower than 78.3%and 75.0%of the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in incidence of mucositis,elevated blood pressure,proteinuria and numbness of hands and feet between the two groups(P>0.05).Conclusion Apatinib mesylate as second-line treatment shows obvious efficacy in advanced non-small cell lung cancer with controllable adverse reactions,so it can be used as a targeted drug for the second-line treatment of non-small cell lung cancer.